BiotechTube

Moxifloxacin 400 mg

ApprovedCompleted
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Side-effect of Antibiotic

Conditions

Side-effect of Antibiotic

Trial Timeline

Jul 1, 2008 → Jul 1, 2010

NCT ID
NCT01302951

About Moxifloxacin 400 mg

Moxifloxacin 400 mg is a approved stage product being developed by Bayer for Side-effect of Antibiotic. The current trial status is completed. This product is registered under clinical trial identifier NCT01302951. Target conditions include Side-effect of Antibiotic.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT01302951ApprovedCompleted

Other Products from Bayer

TelmisartanApproved
82
Clotrimazole vaginal tablet + FluconazoleApproved
82
Levitra (Vardenafil, BAY38-9456)Approved
82
Avelox (Moxifloxacin, BAY12-8039) + Amoxicillin clavulanic acidApproved
82
Rivaroxaban 20 MG + WarfarinApproved
82